– Investigational First-in-Class PCSK9 Synthesis Inhibitor Achieves up to 83% Maximal and 64% Mean Maximum LDL-C Lowering, Comparable to Published Results with Anti-PCSK9 Monoclonal Antibodies, but ...
To promote physical and psychological wellbeing by providing quality mental health care to our patients using evidence-based practice. Perform in-person and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback